Stockscreener 앱 받기
14.72
2.01%
0.29
시간 외 거래:
14.72
전일 마감가:
$14.43
열려 있는:
$14.66
하루 거래량:
4.67M
Relative Volume:
0.80
시가총액:
$7.10B
수익:
$4.45B
순이익/손실:
$205.00M
주가수익비율:
36.80
EPS:
0.4
순현금흐름:
$372.00M
1주 성능:
+6.98%
1개월 성능:
+9.69%
6개월 성능:
+22.16%
1년 성능:
+5.07%
1일 변동 폭
$14.55
$14.79
1주일 범위
$14.01
$14.79
52주 변동 폭
$8.02
$15.78
엘란코 Stock (ELAN) Company Profile
명칭
Elanco Animal Health Inc
전화
877-352-6261
주소
2500 INNOVATION WAY, GREENFIELD
ELAN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
14.72 | 7.10B | 4.45B | 205.00M | 372.00M | 0.40 |
|
RGC
Regencell Bioscience Holdings Ltd
|
10.36 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.08 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.26 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.05 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
엘란코 Stock (ELAN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-09 | 개시 | UBS | Buy |
| 2024-12-02 | 개시 | Leerink Partners | Market Perform |
| 2024-09-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-01-05 | 업그레이드 | Stifel | Hold → Buy |
| 2023-12-19 | 개시 | Jefferies | Buy |
| 2023-12-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-07 | 개시 | Exane BNP Paribas | Outperform |
| 2023-04-20 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-08-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-07-21 | 다운그레이드 | Goldman | Buy → Sell |
| 2022-07-12 | 개시 | Piper Sandler | Neutral |
| 2021-11-18 | 개시 | Morgan Stanley | Overweight |
| 2021-10-28 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2021-06-15 | 업그레이드 | Cleveland Research | Underperform → Neutral |
| 2021-05-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2021-05-11 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2021-04-15 | 개시 | Stifel | Buy |
| 2021-03-22 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2021-02-26 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2020-12-09 | 다운그레이드 | Argus | Buy → Hold |
| 2020-11-09 | 다운그레이드 | Barclays | Overweight → Underweight |
| 2020-08-20 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-08-13 | 재개 | Credit Suisse | Neutral |
| 2020-08-04 | 재개 | Goldman | Buy |
| 2020-07-27 | 다운그레이드 | Cleveland Research | Neutral → Underperform |
| 2020-04-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-10 | 개시 | Raymond James | Mkt Perform |
| 2019-12-19 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-11-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-23 | 개시 | Barclays | Overweight |
| 2019-08-26 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-08-15 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-23 | 개시 | Guggenheim | Neutral |
| 2019-03-18 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-03-13 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-02-12 | 개시 | William Blair | Mkt Perform |
| 2019-01-23 | 개시 | UBS | Sell |
| 2019-01-15 | 개시 | Argus | Buy |
| 2018-10-15 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
엘란코 주식(ELAN)의 최신 뉴스
Zoetis Stock Is Falling. Why the Animal-Health Company Was Downgraded. - Barron's
Elanco (ELAN) Gains Attention Amid Competitive Market Shifts | E - GuruFocus
United States Veterinary Pain Management Market Size, Share & - openPR.com
Harbor Capital Advisors Inc. Has $9.41 Million Stock Position in Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from - GuruFocus
Elanco (ELAN) Awaits European Approval for Zenrelia in Dogs - GuruFocus
Elanco gains positive EMA opinion for Zenrelia for itching in dogs - Seeking Alpha
Elanco (ELAN) Awaits EU Approval for Veterinary Drug Zenrelia | ELAN Stock News - GuruFocus
Elanco’s dog allergy treatment Zenrelia gets positive EU opinion By Investing.com - Investing.com Canada
Elanco Gets 'Positive Opinion' on Canine Itch Drug From European Medicines Agency - marketscreener.com
Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP) | ELAN Stock News - GuruFocus
Elanco Receives Positive Opinion On Zenrelia From EU's Committee - MarketScreener
Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP) – Company AnnouncementFT.com - Financial Times
BiomEdit CEO: Next gen designer probiotics will disrupt the animal and human health market - AgFunderNews
Elanco Animal Health Incorporated (NYSE:ELAN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
ELAN Q1 Earnings Call: Innovation and Product Launches Drive Outlook Amid Macro Uncertainty - Yahoo Finance
Elanco Animal Health Clears Technical Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
Dog Owner Defends Tick Meds Suit Against Elanco, Retailers - Law360
What Makes Elanco Animal Health (ELAN) a New Buy Stock - Yahoo Finance
Is Encompass Health (EHC) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Is the Options Market Predicting a Spike in Elanco Animal Health Stock? - Yahoo Finance
Veterinary Vaccines Market Set to Surge as Global Demand - openPR.com
Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Rating of “Hold” by Analysts - Defense World
Report reveals widespread impact of chronic itch in dogs - Veterinary Practice News
Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief - ACCESS Newswire
Elanco Animal Health Appoints Robert VanHimbergen as Chief Financial Officer - Pet Age
Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief | ELAN Stock News - GuruFocus
Sanders Morris Harris LLC Purchases 81,750 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Equine Healthcare Market Analysis: Trends, Key Players, - openPR.com
Animal Depression Medication Market Detailed in New Research Report | Zoetis Inc., Elanco Animal Health - openPR.com
Ameriprise Financial Inc. Has $1.18 Million Stake in Elanco Animal Health Incorporated (NYSE:ELAN) - Defense World
Companion Animal Health Market -Depth Analysis, Future Trends - openPR.com
Veterinary Vaccines Market Size, Share & Forecast 2025-2033 | - openPR.com
Cetera Investment Advisers Purchases 4,553 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - Defense World
Elanco at Stifel Jaws & Paws: Strategic Growth and Innovation By Investing.com - Investing.com Canada
Elanco appoints Robert VanHimbergen as chief financial officer - Feed Strategy
Elanco appoints VanHimbergen as CFO - Feedstuffs
Transcript : Elanco Animal Health Incorporated Presents at Stifel Jaws & Paws Conference 2025, May-29-2025 08 - marketscreener.com
Elanco names Robert VanHimbergen as new CFO By Investing.com - Investing.com South Africa
Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer - citybiz
How Elanco Plans on Winning in the Pet Wellness Boom - marketscreener.com
Elanco Animal Health Incorporated Announces Change of Executive Vice President - marketscreener.com
Elanco Animal Health Incorporated Reconfirms Earnings Guidance for the Second Quarter and Full Year 2025 - marketscreener.com
Elanco Animal Health Appoints Robert VanHimbergen As CFO, Reaffirms Q2, FY25 Guidance - Nasdaq
Elanco (ELAN) Names Robert VanHimbergen as New CFO | ELAN Stock News - GuruFocus
Elanco Animal Health (ELAN) Maintains Revenue and Earnings Outlook for Q2 | ELAN Stock News - GuruFocus
Elanco Animal Health (ELAN) Reaffirms FY25 Revenue and EBITDA Ou - GuruFocus
Elanco Appoints New CFO to Drive Growth - TipRanks
Elanco names Robert VanHimbergen as new CFO - Investing.com
Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer | ELAN Stock News - GuruFocus
Elanco Animal Health (ELAN) Reaffirms FY25 Revenue and EBITDA Outlook | ELAN Stock News - GuruFocus
엘란코 (ELAN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
엘란코 주식 (ELAN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kurzius Lawrence Erik | Director |
Mar 11 '25 |
Buy |
10.20 |
10,000 |
102,000 |
111,459 |
| HOOVER R DAVID | Director |
Mar 05 '25 |
Buy |
10.90 |
25,000 |
272,558 |
210,000 |
| Harrington Michael J | Director |
Aug 22 '24 |
Buy |
14.85 |
3,500 |
51,974 |
81,094 |
| Simmons Jeffrey N | PRESIDENT, CEO AND DIRECTOR |
Aug 12 '24 |
Buy |
13.01 |
100,000 |
1,300,610 |
145,000 |
1.74%
0.40%
자본화:
|
볼륨(24시간):